UK Regulator Approves GSK's Blujepa for Urinary Tract Infections in Women and Girls

The UK's regulatory agency has approved GSK's Blujepa drug for treating urinary tract infections (UTI) in women and girls. Blujepa is a combination of cefiderocol and pivmecillinam, which is a new antibiotic treatment option for UTIs. GSK is a global biopharma company with a portfolio of vaccines, specialty medicines, and general medicines, including treatments for respiratory and inflammatory conditions.